Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that ER positive, HER2-positive status confers therapeutic sensitivity to Anastrozole, Trastuzumab in patients with Invasive Breast Carcinoma.
This statement is based on a regulatory approval from the Health Service Executive:
HER2 positive metastatic breast cancer (MBC) in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.